Journal of Viral Hepatitis最新文献_第2页

DAA-PASS: A Prospective Evaluation of HCC Recurrence After Direct Acting Antiviral Therapy DAA-PASS：直接抗病毒治疗后HCC复发的前瞻性评估。

IF 2.5 3区医学

Journal of Viral Hepatitis Pub Date : 2025-01-17 DOI: 10.1111/jvh.14056

Amit G. Singal, K. Rajender Reddy, Massimo Colombo, Heather L. Morris, Andrea R. Mospan, Roniel Cabrera, Robin K. Kelley, Ryan D. Kilpatrick, Franco Trevisani, Fabio Farinati, Edoardo G. Giannini, Neil Mehta, Michael W. Fried, Bruno Sangro, the DAA-PASS and ITA.LI.CA Investigators

{"title":"DAA-PASS: A Prospective Evaluation of HCC Recurrence After Direct Acting Antiviral Therapy","authors":"Amit G. Singal, K. Rajender Reddy, Massimo Colombo, Heather L. Morris, Andrea R. Mospan, Roniel Cabrera, Robin K. Kelley, Ryan D. Kilpatrick, Franco Trevisani, Fabio Farinati, Edoardo G. Giannini, Neil Mehta, Michael W. Fried, Bruno Sangro, the DAA-PASS and ITA.LI.CA Investigators","doi":"10.1111/jvh.14056","DOIUrl":"10.1111/jvh.14056","url":null,"abstract":"<div>\u0000 \u0000 Direct-acting antiviral (DAA) therapy is associated with a significant reduction in hepatocellular carcinoma (HCC) incidence among patients with cirrhosis, but data are conflicting about the risk of recurrence following DAA therapy. DAA-PASS was a prospective, pragmatic, observational study designed to estimate the risk of HCC recurrence associated with DAA therapy exposure during routine clinical care. Eligible patients were DAA treatment naive with Barcelona Clinic Liver Cancer (BCLC) stage A. Patients were followed at regular intervals for up to 24 months. To provide additional data, outcomes were compared to the Italian Liver Cancer Group (ITA.LI.CA) cohort. Of 42 patients enrolled, 24 were treated with DAA therapy. Ten HCC recurrence events were observed during the study, with 5 each in DAA-treated and DAA-untreated patients (cumulative incidences of 23 and 37 per 100 PY, respectively). The overall crude hazard ratio (HR) for HCC recurrence associated with DAA therapy was 0.6 (95% CI, 0.2–2.2). In the ITA.LI.CA cohort, HCC recurrence was observed in 193 patients during 24 months of follow-up, resulting in a cumulative incidence rate of 28 per 100 PY. Although limited by small sample size, this prospective study suggests DAA therapy is not associated with increased HCC recurrence risk among patients with a history of complete response to prior HCC therapy.\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 2","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunotherapy Using HBV Vaccine Pulsed DCs and Induced T-Cells Combined Antiviral Drugs in Treatment Naive CHB Patients-A Multi-Centre Phase II Study 使用HBV疫苗脉冲dc和诱导t细胞联合抗病毒药物治疗初发CHB患者的免疫治疗-一项多中心II期研究

IF 2.5 3区医学

Journal of Viral Hepatitis Pub Date : 2025-01-16 DOI: 10.1111/jvh.14045

Yurong Gu, Lin Gu, Lubiao Chen, Jing Li, Chunhong Liao, Yanhua Bi, Zexuan Huang, Wei Cai, Jia Wei, Yuehua Huang

{"title":"Immunotherapy Using HBV Vaccine Pulsed DCs and Induced T-Cells Combined Antiviral Drugs in Treatment Naive CHB Patients-A Multi-Centre Phase II Study","authors":"Yurong Gu, Lin Gu, Lubiao Chen, Jing Li, Chunhong Liao, Yanhua Bi, Zexuan Huang, Wei Cai, Jia Wei, Yuehua Huang","doi":"10.1111/jvh.14045","DOIUrl":"10.1111/jvh.14045","url":null,"abstract":"<div>\u0000 \u0000 Dendritic cells are the most potent antigen-presenting cells in immune therapeutic approaches for chronic hepatitis B (CHB) infection. Here, we developed a clinical trial to evaluate the efficacy and safety of autologous HBV vaccine-pulsed DCs and their induced T cells (HPDCT) in CHB patients. This was a randomised, prospective, open-label, multicentre, superiority study and 309 treatment-naive CHB patients were divided into HPDCT plus nucleos(t)ide analogues (NAs) group (n = 84), NAs mono-therapy group (n = 82), HPDCT plus Peg-interferon (Peg-IFN) group (n = 69), Peg-IFN mono-therapy group (n = 74). Twelve times of HPDCT vaccinations were given intravenously, and all the patients were followed up for 72 weeks. In total, 1836 HPDCT infusions were administered with no obvious toxicity and side effect although few patients had self-limited low fever. More patients got HBsAg loss in those receiving HPDCT therapy. Patients of HPDCT plus Peg-IFN group with HBV DNA < 1 × 107 IU/mL at baseline exhibited earlier, stronger and longer lasting of viral response, especially HBV DNA < 20 IU/mL, than those patients of Peg-IFN mono-therapy group, from week 24 till week 72 (p < 0.05). Comparable efficacy was observed between the patients of HPDCT plus NAs group and NAs mono-therapy groups. In addition, CD25 on CD8+ T cells and HBV-specific CD8+ T cell increased significantly in patients of HPDCT combined antiviral drugs therapy. HPDCT combined with antiviral drugs was safe and able to enhance T cell immunity. Furthermore, HPDCT combined with Peg-IFN could provide an incremental benefit to patients with baseline levels of lower HBV DNA.\u0000 Trial Registration: ClinicalTrials.gov identifier: NCT01935635\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 2","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Heterogeneity in Risk and Implications for Hepatitis C Reinfection in People Who Inject Drugs in England 英国注射吸毒者丙型肝炎再感染风险的异质性及其意义

IF 2.5 3区医学

Journal of Viral Hepatitis Pub Date : 2025-01-16 DOI: 10.1111/jvh.14052

Bryn Hilton, Daniela De Angelis, Holly Mitchell, Ross Harris

{"title":"Heterogeneity in Risk and Implications for Hepatitis C Reinfection in People Who Inject Drugs in England","authors":"Bryn Hilton, Daniela De Angelis, Holly Mitchell, Ross Harris","doi":"10.1111/jvh.14052","DOIUrl":"10.1111/jvh.14052","url":null,"abstract":"Chronic hepatitis C virus (HCV) infection is associated with significant morbidity, mortality and health economic burden. Over 90% of HCV cases in England occur in people who inject drugs (PWID). Current treatments for HCV are effective but do not protect against reinfection. This research characterised HCV infection and reinfection risk in PWID in England using 2011–2021 data from the annual, cross-sectional, bio-behavioural survey of PWID, Unlinked Anonymous Monitoring. Risk factors for HCV infection were explored using multivariable logistic regression. Shared frailty models for the force of infection (FOI) were used to estimate the risk of HCV infection throughout injecting career with unmeasured risk variation modelled using gamma-shaped frailty distributions. HCV reinfection rates were derived using the frailty distributions of FOI models fitted to UAM data. Infection rates were highest in the first year of injecting (24 per 100 person-years) but fell to between 5 and 8 infections per 100 person-years subsequently. The estimated average annual risks of HCV primary infection and reinfection were 10.0% and 14.2%, indicating a 42% higher risk of reinfection compared to primary infection. Even those with no a priori risk factors were predicted to have high rates of reinfection if previously infected. These findings support the recognition of primary HCV infection as an independent risk factor for reinfection in PWID and emphasise the importance of reducing high-risk behaviours to prevent HCV reinfection following treatment of primary infection. Public health policies must recognise the importance of preventing reinfection in efforts to reduce HCV infection prevalence.","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 2","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11736538/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Disease and Economic Burden of HBV and HCV in Ethiopia 埃塞俄比亚HBV和HCV的疾病和经济负担。

IF 2.5 3区医学

Journal of Viral Hepatitis Pub Date : 2025-01-16 DOI: 10.1111/jvh.14053

Alexis S. Voeller, Asgeir Johannessen, Zebideru Zewdie Abebe, Wegene Adugna, Ivane Gamkrelidze, Eleni Seyoum, Lia Tadesse Gebremedhin, Mirtie Getachew Meselu, Seblewongel Abate Nigussie, Asmamaw Silesh, Homie Razavi, Devin Razavi-Shearer, Ghion Tirsite, Hailemichael Desalegn

{"title":"The Disease and Economic Burden of HBV and HCV in Ethiopia","authors":"Alexis S. Voeller, Asgeir Johannessen, Zebideru Zewdie Abebe, Wegene Adugna, Ivane Gamkrelidze, Eleni Seyoum, Lia Tadesse Gebremedhin, Mirtie Getachew Meselu, Seblewongel Abate Nigussie, Asmamaw Silesh, Homie Razavi, Devin Razavi-Shearer, Ghion Tirsite, Hailemichael Desalegn","doi":"10.1111/jvh.14053","DOIUrl":"10.1111/jvh.14053","url":null,"abstract":"As the second most populated country in Africa, Ethiopia needs public health measures to control diseases that impact its population. The goal of this study is to analyse disease burdens of HBV and HCV, while also highlighting their estimated associated costs for the country. A literature review and a Delphi process reflecting input of Ethiopian experts and the National Viral Hepatitis Technical Working Group were used to complement mathematical modelling to estimate HBV and HCV disease and economic burdens. Two scenarios were created for HCV: 2023 base and WHO elimination. For HBV, three scenarios were created: 2023 base, WHO elimination and universal birth dose. Using current country costs, each scenario was also examined through an economic lens. There were an estimated 7.6 million HBV infections in 2023. To impact transmission, a universal birth dose and pregnant women screening program would allow Ethiopia to vaccinate approximately 3.9 million infants annually, with a budget of $4.68 million USD, meeting the WHO prevalence elimination target (≤ 0.1% in ≤ 5-year-olds) by 2043. Ethiopia had an estimated 690,000 HCV infections in 2023. To achieve HCV elimination, the country would need to expand screening and treatment to 74,000 individuals annually with a peak budget of $12 million USD per year until 2032, decreasing to less than $2 million USD in 2035. Ethiopia can begin making steps towards elimination of HBV through expansion of birth dose vaccination. However, larger investments will be needed to scale-up treatment and diagnosis interventions for both diseases.","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 2","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11736537/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Resistance-Associated Substitution Testing Trends and Impact on HCV Treatment Outcomes in Canada: A CanHepC-CANUHC Analysis

IF 2.5 3区医学

Journal of Viral Hepatitis Pub Date : 2025-01-09 DOI: 10.1111/jvh.14058

Himain Perera, Haris Imsirovic, Gisela Macphail, Duncan Webster, Chris Fraser, Sergio Borgia, Hongqun Liu, Sam Lee, Jordan J. Feld, Curtis Cooper, the Canadian Network Undertaking Against Hepatitis C (CANUHC) Cohort Investigator Team

{"title":"Resistance-Associated Substitution Testing Trends and Impact on HCV Treatment Outcomes in Canada: A CanHepC-CANUHC Analysis","authors":"Himain Perera, Haris Imsirovic, Gisela Macphail, Duncan Webster, Chris Fraser, Sergio Borgia, Hongqun Liu, Sam Lee, Jordan J. Feld, Curtis Cooper, the Canadian Network Undertaking Against Hepatitis C (CANUHC) Cohort Investigator Team","doi":"10.1111/jvh.14058","DOIUrl":"10.1111/jvh.14058","url":null,"abstract":"<div>\u0000 \u0000 Resistance-associated substitutions (RASs) are mutations within the hepatitis C (HCV) genome that may influence the likelihood of achieving a sustained virological response (SVR) with direct acting antiviral (DAA) treatment. Clinicians conduct RAS testing to adapt treatment regimens with the intent of improving the likelihood of cure. The Canadian Network Undertaking against Hepatitis C (CANUHC) prospective cohort consists of chronic HCV patients enrolled between 2015 and 2023 across 17 Canadian sites. Utilisation of RAS testing was assessed across demographics, clinical characteristics and years. SVR was described for the overall cohort and compared across populations of patients with historically negative predictors of SVR. The detection of key RASs and how this information influenced DAA selection were assessed. 2434 patients were identified with information on RAS testing. 98.3% achieved SVR. Out of the 227 patients tested for RAS, 147 (64.8%) had any detected RAS, and 84 (37.0%) had an NS5A RAS. The proportion of patients with SVR did not differ between RAS-tested (98.3%) and non-tested patients (98.3%; p = 0.99). SVR in those with an NS5a RAS was similar (98.6%) to the overall SVR proportion. Proportions with SVR did not differ between those with and without RAS testing in key subgroups (genotype 1a, genotype 3, prior treatment, cirrhosis). The specific DAA regimen and the addition of ribavirin were not associated with SVR outcome. RAS testing has a minimal influence on antiviral treatment selection. Going forward, there is a reduced role for RAS testing in most clinical scenarios.\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 2","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143055966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patient Source of Referral Is a Key Determinant of Subsequent Retention in Care for Young Chronic Hepatitis B Patients 患者转诊来源是年轻慢性乙型肝炎患者后续护理的关键决定因素。

IF 2.5 3区医学

Journal of Viral Hepatitis Pub Date : 2025-01-09 DOI: 10.1111/jvh.14059

David Mutimer, Maxine Brown, Jacqueline Logan, Chayarani Kelgeri

{"title":"Patient Source of Referral Is a Key Determinant of Subsequent Retention in Care for Young Chronic Hepatitis B Patients","authors":"David Mutimer, Maxine Brown, Jacqueline Logan, Chayarani Kelgeri","doi":"10.1111/jvh.14059","DOIUrl":"10.1111/jvh.14059","url":null,"abstract":"Hepatitis B elimination objectives can only be realised if new patient linkage to care is matched by long-term patient retention in care. We previously showed in adult chronic hepatitis B (CHB) patients that retention in care was inferior in younger patients and in patients from non-Asian ethnicities. The present study explores further the rates and determinants of loss to follow-up in a cohort of 271 young patients (aged 16–21 years at baseline). 16% of patients were lost to follow-up after a single consultation, and retention in care at 5 and 10 years was 53.7% and 45.9%, respectively. Retention in care was strongly associated with the source of patient referral and was superior for patients referred from the antenatal clinic and those transitioned from paediatric care (68% retention at 5 years for both sources) compared with those from “other” sources (36% at 5 years). In multivariate analyses, patient source of referral and distance of current residence from the Hepatitis Outpatient Clinic were the significant determinants of loss to follow-up. Retention in care may have been promoted by the transition process for those diagnosed in childhood and by the repeated referral from the antenatal clinic of women who had multiple pregnancies during the observation period. Only 20% of asylum seekers and referrals from genitourinary clinics were retained in follow-up at 10 years from baseline. This identifies a group of patients who do not access medical care, cannot benefit from treatment, and who may constitute a long-term public health risk.","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 2","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11715132/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142950778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimization of the Use of APRI and FIB-4 for Ruling Out Liver Cirrhosis in Chronic Hepatitis B Patients With Normal Alanine Aminotransferase 丙氨酸转氨酶正常的慢性乙型肝炎患者应用APRI和FIB-4排除肝硬化的优化

IF 2.5 3区医学

Journal of Viral Hepatitis Pub Date : 2025-01-03 DOI: 10.1111/jvh.14057

Zhiyi Zhang, Jian Wang, Li Zhu, Yiguang Li, Shaoqiu Zhang, Yifan Pan, Yuxin Chen, Shengxia Yin, Xiaomin Yan, Xingxiang Liu, Yuanwang Qiu, Chao Wu, Jie Li, Chuanwu Zhu, Rui Huang

{"title":"Optimization of the Use of APRI and FIB-4 for Ruling Out Liver Cirrhosis in Chronic Hepatitis B Patients With Normal Alanine Aminotransferase","authors":"Zhiyi Zhang, Jian Wang, Li Zhu, Yiguang Li, Shaoqiu Zhang, Yifan Pan, Yuxin Chen, Shengxia Yin, Xiaomin Yan, Xingxiang Liu, Yuanwang Qiu, Chao Wu, Jie Li, Chuanwu Zhu, Rui Huang","doi":"10.1111/jvh.14057","DOIUrl":"10.1111/jvh.14057","url":null,"abstract":"<div>\u0000 \u0000 The exclusion of cirrhosis is important in chronic hepatitis B (CHB) patients with normal alanine aminotransferase (ALT). We aimed to optimise the performance of the aspartate aminotransferase to platelet ratio index (APRI) and fibrosis score based on four factors (FIB-4) to exclude cirrhosis in these patients. Five hundred and eighty four patients with normal ALT who underwent liver biopsy were included in the study. The patients were divided into derivation and external validation sets. A grid search method was used to identify new cut-offs with a negative predictive value (NPV) of > 95% and a sensitivity of > 90% for detecting cirrhosis. The proportion of patients with cirrhosis in the derivation and validation sets was 19.4% and 7.5%, respectively. The conventional cut-offs of APRI (77.6%) and FIB-4 (41.8%) had high rates of cirrhosis misclassification. A new APRI cut-off of 0.21 had a sensitivity of 97.0% and an NPV of 95.6%, and only two (3.0%) patients with cirrhosis were misclassified in the derivation set. Using a new FIB-4 cut-off of 0.53, with a sensitivity of 98.5% and NPV of 96.2%, only one (1.5%) patient with cirrhosis was misclassified. External validation showed similar results. Using the new cut-offs of APRI and FIB-4, cirrhosis could be completely excluded for HBeAg-positive patients or those aged > 40 years. The conventional cut-offs had high misclassification rates for cirrhosis. The new cut-offs of APRI (≤ 0.21) and FIB-4 (≤ 0.53) could be used to exclude cirrhosis in CHB patients with normal ALT levels with a low misclassification rate.\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 2","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142921983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Qualitative Systematic Review of Barriers and Facilitators to Hepatitis B and C Programmes in Prisons 监狱中乙型和丙型肝炎规划的障碍和促进因素的定性系统评价。

IF 2.5 3区医学

Journal of Viral Hepatitis Pub Date : 2024-12-28 DOI: 10.1111/jvh.14049

Heidi Emery, Catrin Evans, Kathryn Jack, Elisa Martello, Princella Seripenah, Fatima Aiyelabegan, Surakshya Dhungana, Titus Joseph, Dirontsho Koboto, Joanne R. Morling, James Stewart-Evans, Emma Wilson, Jo Leonardi-Bee

{"title":"A Qualitative Systematic Review of Barriers and Facilitators to Hepatitis B and C Programmes in Prisons","authors":"Heidi Emery, Catrin Evans, Kathryn Jack, Elisa Martello, Princella Seripenah, Fatima Aiyelabegan, Surakshya Dhungana, Titus Joseph, Dirontsho Koboto, Joanne R. Morling, James Stewart-Evans, Emma Wilson, Jo Leonardi-Bee","doi":"10.1111/jvh.14049","DOIUrl":"10.1111/jvh.14049","url":null,"abstract":"The prevalence of viral hepatitis among people in prisons is higher than in the general population. Screening, treatment and vaccination programmes exist within prisons to reduce the incidence of hepatitis, although lower uptake has often been reported compared to similar programmes outside of prisons. We conducted a systematic review of qualitative evidence to explore the barriers and facilitators to hepatitis B and C reduction programmes in prisons from the perspectives of people in prison, custodial staff and prison healthcare staff. Comprehensive searches of five databases (to November 2023) yielded 28 studies for review inclusion. Four synthesised findings were identified: (i) accurate, up-to-date knowledge of viral hepatitis disease and treatment among people in prison and staff is a facilitator to programme uptake, particularly when imparted by a trusted source; (ii) personal subjective and relative views have a bearing on participation with the programme; (iii) social interactions and relationships both within the community of people in prison and between them and staff groups influence participation in the programmes; and (iv) the organisational structure of the prison and healthcare services within it affect programme participation. Based on these findings, we make recommendations for the adaptation of viral hepatitis programmes to individual custodial settings thereby improving equitable programme access and hepatitis B and C reduction in this complex environment.","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 2","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11681497/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142895666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Features and Transition of Acute Hepatitis B Virus Infection 急性乙型肝炎病毒感染的临床特征和转变。

IF 2.5 3区医学

Journal of Viral Hepatitis Pub Date : 2024-12-27 DOI: 10.1111/jvh.14048

Huali Wang, Jian Wang, Shaoqiu Zhang, Shuai Zhang, Zhiyi Zhang, Jiacheng Liu, Yifan Pan, Chao Jiang, Ye Xiong, Tao Fan, Rui Huang, Li Li

{"title":"Clinical Features and Transition of Acute Hepatitis B Virus Infection","authors":"Huali Wang, Jian Wang, Shaoqiu Zhang, Shuai Zhang, Zhiyi Zhang, Jiacheng Liu, Yifan Pan, Chao Jiang, Ye Xiong, Tao Fan, Rui Huang, Li Li","doi":"10.1111/jvh.14048","DOIUrl":"10.1111/jvh.14048","url":null,"abstract":"<div>\u0000 \u0000 Acute hepatitis B (AHB) is generally a self-limiting illness in adults and most patients achieve hepatitis B surface antigen (HBsAg) clearance within 6 months. We aimed to investigate the proportion and influencing factors of chronic outcome in adult AHB patients. A total of 126 consecutive AHB patients were included between January 2013 and October 2018. Multivariate regression analysis was conducted to evaluate the influencing factor of HBsAg clearance. Fourteen (11.1%) patients failed to achieve HBsAg clearance within 6 months. Among them, nine patients achieved HBsAg clearance within 6–12 months, while five patients had persistent HBsAg positive over 1 year. Patients with HBsAg clearance had lower baseline antibody to hepatitis B core antigen (anti-HBc) (7.0 S/CO vs. 8.0 S/CO, p = 0.090) and HBsAg levels than those with chronicity of AHB. Multivariate analysis revealed that HBsAg ≤ 250 IU/mL (HR 3.008, IQR 1.877, 4.820, p < 0.001) and anti-HBc levels (HR 0.830, IQR 0.755, 0.912, p < 0.001) was significantly associated with HBsAg clearance. Anti-HBc remained an independent predictor of HBsAg clearance in different HBsAg subgroups. Patients with HBsAg > 250 IU/mL (p < 0.001) and high anti-HBc (p = 0.001) had lower cumulative HBsAg clearance rates than those with low HBsAg and anti-HBc. 11.1% of AHB patients did not achieve HBsAg clearance within 6 months, while the proportion of patients with persistent HBsAg positive decreased to 4.0% after 1 year. Combination of baseline HBsAg and anti-HBc levels could identify patients who might have a possible risk of chronicity following AHB.\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 2","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142895672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hepatitis B Patients' Adherence to Treatment in Relation to Knowledge, Attitudes, and Practices (KAP) in the West Bank, Palestine, 2022–2023 2022-2023年巴勒斯坦西岸乙型肝炎患者与知识、态度和实践（KAP）相关的治疗依从性

IF 2.5 3区医学

Journal of Viral Hepatitis Pub Date : 2024-12-23 DOI: 10.1111/jvh.14055

Ayham Sawalmeh, Emily White Johansson, Danis Kostas, Dia'a Hjaijeh

{"title":"Hepatitis B Patients' Adherence to Treatment in Relation to Knowledge, Attitudes, and Practices (KAP) in the West Bank, Palestine, 2022–2023","authors":"Ayham Sawalmeh, Emily White Johansson, Danis Kostas, Dia'a Hjaijeh","doi":"10.1111/jvh.14055","DOIUrl":"10.1111/jvh.14055","url":null,"abstract":"Hepatitis B is an infectious disease that inflicts high health and economic costs on the healthcare system. Poor adherence to treatment increases that cost. We aimed to assess the levels of knowledge, attitudes and practices (KAP) among patients in the West Bank, Palestine, and identify factors associated with good adherence. We conducted a cross-sectional study surveying hepatitis B patients visiting primary healthcare during October 2022 until June 2023 using an interviewer-administered questionnaire covering qualitative and quantitative aspects regarding hepatitis B. We considered adherence as good if participants received > 90% of their monthly prescription antiviral doses. Among 386 participants, the median age was 45 years (range 20–81); 80% had good adherence to treatment. Mean knowledge score was 11.4 (on a 13-point scale), mean attitude score was 3.4 (on a 4-point scale), mean practices score was 6 (on a 7-point scale) and the mean overall KAP score was 21.8 (on a 24-point scale). KAP components (Cronbach alpha = 0.820) were correlated with good adherence (p < 0.001). After adjustment for other factors, participants with good KAP scores had better adherence to treatment than those without (prevalence ratio: 1.41, 95% CI: 1.10–1.84, p-value = 0.011). We recommend investment in education and awareness campaigns to improve adherence.","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11667092/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142882185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0